Page 8; Line 52. The first part of this sentence states "the placebo intervention will enhance MMT outcomes…" I'm not sure this is consistent with what the authors have written previously. It may be more accurate to write, "…the placebo intervention will achieve equivalent MMT outcomes (decreased positive urine screens and increased treatment retention) at lower mean doses of methadone.
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GENERAL COMMENTS
This manuscript describes a randomized control trial looking at dose extending for methadone maintenance treatment. While this is an interesting premise, I have the following concerns about the study design: 1. Burden of disease: it would be helpful to know the average doses of methadone in their treatment program -are high doses really an issue? Moreover, there is some controversy over whether QT prolongation is dose dependent and, more importantly, if the clinical outcome (rather than the proxy measure of QT prolongation) of Torsades de Pointes is dose dependent. I think the authors should present some evidence on present day programs having high average methadone doses and on if keeping doses lower really does prevent Torsades. 2. I am concerned about the study design with respect to the use of placebo and blinding: in this case the participants will know which group they are assigned to and the subjective fear they have of their opioid dose not being high enough is not addressedthey will know that the dose extending pill that they are receiving is a placebo and this will still factor into their subjective withdrawal symptoms and requests for a higher dose. 3. Finally, it is hard to understand how their treating clinicians would not become aware of the participants' study assignment: surely the clinicians will hear from their patients about the dose extenders and so it cannot really be single-blind. Finally, clinicians will have a plethora of clinical experience in treating opioid use disorder patients with methadone and have some preconceptions of reasonable therapeutic dose ranges of methadone. If they are presented with a patient on a low dose of methadone with mild subjective withdrawal symptoms they may be more likely to increase the dose based purely on the low dose and previous clinical experience that most of their patients do well on higher doses. It seems that the only thing that could really get at the answer the authors are seeking is to keep participants blind to their methadone dose altogether and have dose increases made only by a preset protocol using a threshold score on a subjective withdrawal symptom scale.
In summary, this is an interesting question -i.e. how much do subjective opioid withdrawal symptoms and fear of withdrawal play into potentially unnecessary and harmful dose increases -but I would like a stronger case to made that these dose increases are actually harmful and are a prevalent problem and I think the protocol needs to be adjusted so that participants are blind to their dose and dose adjustments are made based on the results of a subjective symptom scale.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Thank you for the opportunity to review manuscript ID bmjopen-2018-026604, entitled, Open-label dose-extending placebos for opioid use disorder: a protocol for a randomized controlled trial. This manuscript describes an ethical and well-designed study to assess the effectiveness of a doseextending placebo as a novel and potentially effective adjunct treatment for OUD. The background, conceptualization, and description of procedures are excellent. Figure 1 is very helpful. The paper is very well organized and the writing is clear and concise. I have only minor comments.
1. It may be important to briefly mention the clinical criteria (e.g. patient subjective mood, craving, substance use) that blinded clinicians will use to determine the need for dose escalation at week 3. This clinical decision determines the final maintenance dose (i.e. dependent variable). Evaluating these criteria through chart review at the trial's conclusion may be important for understanding which clinical criteria most influenced dose escalation -and possibly shed light on the underlying mechanism for placebo. If treatment providers are required to interact with research subjects or nursing staff in order to evaluate the need for dose escalation, it could lead to unblinding.
We thank the reviewer for his very positive feedback. We agree that we did not give the readers sufficient understanding of how methadone dose adjustments are determined in our clinic. We have addressed this missing information in a new section under Study Design and Procedures entitled "Blinding."
2. Page 7; What is "Bayesian brain function"?
We have removed unnecessary reference to this term as we agree that without context, it is confusing.
3. Page 6; "raisk" should be "risk".
This typo has been corrected.
4. Page 7; "insert" should be "inert"
5. Page 8; Line 52. The first part of this sentence states "the placebo intervention will enhance MMT outcomes…" I'm not sure this is consistent with what the authors have written previously. It may be more accurate to write, "…the placebo intervention will achieve equivalent MMT outcomes (decreased positive urine screens and increased treatment retention) at lower mean doses of methadone.
Thank you for the suggestion to clarify; we have changed this sentence to reflect the fact that in addition to the hypothesized impact of PDE on methadone dose (primary outcome), we also anticipate that the PDE intervention will have a significant impact on outcomes associated with methadone treatment; namely, treatment retention and objective (urine screens) and subjective (selfreport) measures of participant drug use while they are enrolled in methadone treatment (secondary outcomes).
1. Burden of disease: it would be helpful to know the average doses of methadone in their treatment program -are high doses really an issue? Moreover, there is some controversy over whether QT prolongation is dose dependent and, more importantly, if the clinical outcome (rather than the proxy measure of QT prolongation) of Torsades de Pointes is dose dependent. I think the authors should present some evidence on present day programs having high average methadone doses and on if keeping doses lower really does prevent Torsades.
We thank the reviewer for the concern, and realize that perhaps the intention of our study, which is to enhance methadone treatment outcomes, was not communicated sufficiently. We do cite evidence to suggest that higher doses of methadone may be a significant reason for treatment attrition10 and may put MAT patients at higher risk for cardiotoxicity11-13. This risk would be mitigated if equivalent treatment outcomes could be achieved at lower doses of methadone. We suggest that all things being equal (i.e., non-inferior outcomes), lower levels of any medication, including methadone, would be preferred by a treating clinician. So, we chose to focus on three-month methadone dose (in milligrams) as a straight-forward, quantifiable primary outcome that might be different between the treatment arms. This said, however, it is not the explicit aim of our intervention to decrease methadone doses in our clinic. Instead, we are testing the notion that placebo effects may be used as an effective adjunct to methadone treatment to enhance treatment outcomes-of which, lower methadone dose (as a function of minimized methadone dose escalation) might be just one. Indeed, we are open to the fact that the placebo adjunct could yield therapeutic benefits on treatment retention and on in-treatment drug use. Thus, we are collecting retention data for our participants as well as indicators of drug use that include urine toxicology screening and participant self-reported drug use. To help clarify this subtle (but important) distinction in the aims of our study, we have added a sentence to the end of the third paragraph in the Introduction, as well as to the Objectives section of the manuscript.
2. I am concerned about the study design with respect to the use of placebo and blinding: in this case the participants will know which group they are assigned to and the subjective fear they have of their opioid dose not being high enough is not addressed -they will know that the dose extending pill that they are receiving is a placebo and this will still factor into their subjective withdrawal symptoms and requests for a higher dose.
Addressed below 3. Finally, it is hard to understand how their treating clinicians would not become aware of the participants' study assignment: surely the clinicians will hear from their patients about the dose extenders and so it cannot really be single-blind. Finally, clinicians will have a plethora of clinical experience in treating opioid use disorder patients with methadone and have some preconceptions of reasonable therapeutic dose ranges of methadone. If they are presented with a patient on a low dose of methadone with mild subjective withdrawal symptoms they may be more likely to increase the dose based purely on the low dose and previous clinical experience that most of their patients do well on higher doses. It seems that the only thing that could really get at the answer the authors are seeking is to keep participants blind to their methadone dose altogether and have dose increases made only by a preset protocol using a threshold score on a subjective withdrawal symptom scale.
We thank the reviewer for her clear insight on the problem of blinding. As mentioned above, we feel that the information that was previously provided in the earlier version of this manuscript was insufficient for a reader's understanding of how dose alterations are managed in our clinic. To address this gap, we have added a new section under Study Design and Procedures entitled "Blinding" that addresses how we are handling clinician, participant and physician blinding methods.
